Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Perioperative nivolumab shows significant efficacy in lung cancer treatment

Written by | 18 May 2024

When compared with pre-surgical (neoadjuvant) chemotherapy only, adding perioperative immunotherapy before and after surgery significantly improves event-free survival in patients with resectable early-stage non-small cell lung cancer (NSCLC),… read more.

Gut bacteria important for overcoming milk allergy

Written by | 19 Mar 2024

Researchers led by Hiroshi Ohno at the RIKEN Center for Integrative Medical Sciences in Japan have discovered a link between gut bacteria and the success of milk-allergy oral… read more.

Survival benefit from frontline immunotherapy in progression-free non–small cell lung cancer peaks at 2 years

Written by | 13 Jun 2023

For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.

Study shows promising results for immunotherapy targeting skin cancer

Written by | 28 Apr 2023

A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer. The study, published today in Nature Communications by researchers from King’s College London… read more.

Gut bacteria play role in CAR-T cancer therapy

Written by | 16 Apr 2023

CAR-T cell therapy has been shown to be highly effective in treating some cancers. However, responses to this relatively new form of immunotherapy can vary, making it difficult… read more.

Immunotherapy after surgery provides significant, durable benefit for high-risk bladder patients

Written by | 17 Feb 2023

Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral… read more.

New immunotherapy holds promise for ovarian cancer

Written by | 8 Feb 2023

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system’s T cells are programmed to attack tumour cells, is effective in mice with ovarian… read more.

Researchers find treatment options for patients whose blood cancer relapses after CAR-T

Written by | 9 Nov 2022

Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known… read more.

Immunotherapy before targeted therapy improves survival in advanced melanoma

Written by | 4 Oct 2022

Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially… read more.

Immunotherapy drug did not increase surgery complications, study finds

Written by | 10 Sep 2022

A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery…. read more.

Peanut allergy treatment safest when started for infants under 12 months, researchers find

Written by | 22 Jun 2022

UBC researchers demonstrated in 2019 that pre-schoolers can safely overcome peanut allergies with a treatment called oral immunotherapy. Now they have evidence that the earlier pre-schoolers start this… read more.

How ovarian cancer defies immunotherapy

Written by | 12 Apr 2022

Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.